Galantamine for Alzheimer's disease (Q24246158)

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Use of galantamine to treat vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galanthamine in Alzheimer's disease : a new alternative to tacrine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

The effects of galantamine treatment on caregiver time in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine: a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

The pharmacology of galanthamine and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

Galantamine hydrobromide: an agent for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB2

7 January 2021